Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 8Phase 3 3Phase 1/2 3

Status

Completed 8Active not recruiting 8Unknown 3Recruiting 2Withdrawn 1Suspended 1

Sponsor Class

INDUSTRY 5OTHER 3

Study Type

Interventional 8

Sponsor

Cancer Type

Breast 4Tumor-Agnostic 2Gastrointestinal 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Phase 2 × Completed × ipatasertib × Clear all
NCT03498521 2025-11-19

CUPISCO

Hoffmann-La Roche

Phase 2 Completed
529 enrolled 16 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

German Cancer Research Center

Phase 2 Completed
72 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04632992 2025-01-08

MyTACTIC

Genentech, Inc.

Phase 2 Completed
252 enrolled 27 charts

Advanced Unresectable or Metastatic Solid Malignancy

NCT04464174 2024-07-26

PATHFINDER

MedSIR

Phase 2 Completed
54 enrolled
Breast

Triple Negative Breast Neoplasms

NCT03395899 2024-06-18

ECLIPSE

Queen Mary University of London

Phase 2 Completed
71 enrolled
Breast

Breast Neoplasms

NCT01896531 2022-03-02

A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Genentech, Inc.

Phase 2 Completed
153 enrolled 16 charts
Gastrointestinal

Stomach Neoplasms

NCT02162719 2021-03-10

LOTUS

Genentech, Inc.

Phase 2 Completed
124 enrolled 26 charts
Breast

Breast Neoplasms

NCT02301988 2018-10-17

A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer

Genentech, Inc.

Phase 2 Completed
151 enrolled 22 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡